Why two prescription labels look nothing alike

Two formats, both current

Put two prescription drug labels side by side and they can be structured completely differently. One opens with a boxed summary and numbered sections. The other runs as a sequence of headings with no summary at the top.

Neither is out of date. Section 201.56 of title 21 keeps both formats in force and assigns each product to one of them.

Which one applies is not about the drug. It is about the paperwork history behind it.

Companion pieces here describe what a modern label contains section by section. This one is about the split itself, and about a rule that lives only on the older side.

The rules that apply to both

Paragraph (a) of section 201.56 sets three requirements that no format escapes, and they are worth reading as a standard for any product claim.

The labeling "must contain a summary of the essential scientific information needed for the safe and effective use of the drug."

It "must be informative and accurate and neither promotional in tone nor false or misleading in any particular." It must be updated "when new information becomes available that causes the labeling to become inaccurate, false, or misleading."

And the evidence standard: labeling "must be based whenever possible on data derived from human experience." No implied claims or suggestions of drug use may be made "if there is inadequate evidence of safety or a lack of substantial evidence of effectiveness."

The third requirement adds a labeling duty about animal data. Conclusions based on animal data that are necessary for safe and effective human use "must be identified as such and included with human data in the appropriate section of the labeling."

The line between the two formats is a set of dates

Paragraph (b) draws it, and it draws it entirely by application history.

The newer format applies to products whose application or efficacy supplement was approved between June 30, 2001 and June 30, 2006. It also applies where one was pending on June 30, 2006, or was submitted at any time on or after that date.

Everything else falls the other way, in one sentence: products not so described "are subject to the labeling requirements in paragraph (e) of this section and § 201.80."

Paragraph (c) then sets out the conversion schedule that moved products across, running in annual steps keyed to when each application was approved, with the last of them due by June 30, 2013.

So a drug approved before that window, and never the subject of a later efficacy supplement, keeps the older format indefinitely. That is not a lapse. It is what the regulation provides.

What the older format asks for first

Section 201.80 sets out the older structure, and its opening section is a good illustration of the difference in feel.

Under the Description heading, the labeling must give the proprietary and established names. It must also give "The type of dosage form and the route of administration to which the labeling applies," and the ingredient information required for the label itself.

It must state "If the product is sterile, a statement of that fact." It must give "The pharmacological or therapeutic class of the drug," and "The chemical name and structural formula of the drug."

Where appropriate it adds "other important chemical or physical information, such as physical constants, or pH."

That is a chemistry-forward opening. The newer format leads with a summary aimed at prescribing decisions instead.

The rule about laboratory and animal data

This is the substantive provision worth knowing, and it sits in section 201.80(b).

The clinical pharmacology section must contain "a concise factual summary of the clinical pharmacology and actions of the drug in humans." In vitro and animal data may appear there, but only where "essential to a description of the biochemical and/or physiological mode of action of the drug or is otherwise pertinent to human therapeutics."

There is also a duty to disclose a gap. Where the pharmacological mode of action is unknown, or important human metabolic or pharmacokinetic data are unavailable, "the labeling shall contain a statement about the lack of information."

Then comes the restriction. Data showing activity or effectiveness in laboratory or animal tests, "that have not been shown by adequate and well-controlled clinical studies to be pertinent to clinical use," may be included "only under the following circumstances."

For anti-infective drugs, in vitro data may appear "if the data are immediately preceded by" a prescribed sentence stating that the following in vitro data are available but their clinical significance is unknown.

For every other class, such data "may be used only if a waiver is granted" under section 201.58 or a provision of the new drug application rules.

What a waiver is here

Section 201.58 is four sentences long, and it makes the waiver route concrete rather than theoretical.

An applicant "may ask the Food and Drug Administration to waive any requirement under §§ 201.56, 201.57, and 201.80."

The request must be in writing and goes to a named director at the relevant center, with a postal address printed in the regulation.

And the outcome has to be recorded. "The waiver must be granted or denied in writing by the Director or the Director's designee."

So on an approved product, laboratory or animal data outside the anti-infective carve-out reaches the label only through a written request that produced a written grant.

Why this is the useful part for a peptide reader

Because mechanism claims in this market are usually built on exactly the kind of data section 201.80(b)(2) restricts.

A cell-culture result, a receptor binding figure or a rodent study is laboratory or animal data. On an approved product's label under the older format, such data cannot simply be added because it is interesting.

For one class it may appear, and only behind a sentence saying its clinical significance is unknown. For every other class it needs a waiver granted in writing.

A product page is not a drug label and is not governed by these sections. That is the point of the comparison rather than a reason to skip it. The same evidence that would need a written waiver to sit on a label sits on a marketing page with no preface at all.

This page describes what the regulations say. It names no seller, assesses nobody's compliance, and is not legal advice. Section 201.57, which sets the content of the newer format, is covered in the companion pieces rather than here.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. Title 21 Code of Federal Regulations section 201.56, Requirements on content and format of labeling for human prescription drug and biological products — Electronic Code of Federal Regulations, Office of the Federal Register, December 2014
2. Title 21 Code of Federal Regulations section 201.58, Waiver of labeling requirements — Electronic Code of Federal Regulations, Office of the Federal Register, April 2015
3. Title 21 Code of Federal Regulations section 201.80, Specific requirements on content and format of labeling for human prescription drug and biological products; older drugs not described in § 201.56(b)(1) — Electronic Code of Federal Regulations, Office of the Federal Register, December 2014